Home >> Pharmaceuticals >> Food & Beverage >>

Nanomerics Ltd - Product Pipeline Review - 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 28 | Code: MRS - 18284

Nanomerics Ltd - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Nanomerics Ltd - Product Pipeline Review - 2015’, provides an overview of the Nanomerics Ltd’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nanomerics Ltd’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Nanomerics Ltd including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Nanomerics Ltd’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Nanomerics Ltd’s pipeline products

Reasons to buy

- Evaluate Nanomerics Ltd’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Nanomerics Ltd in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Nanomerics Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Nanomerics Ltd and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nanomerics Ltd
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Nanomerics Ltd and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Nanomerics Ltd Snapshot 5
Nanomerics Ltd Overview 5
Key Information 5
Key Facts 5
Nanomerics Ltd - Research and Development Overview 6
Key Therapeutic Areas 6
Nanomerics Ltd - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Nanomerics Ltd - Pipeline Products Glance 10
Nanomerics Ltd - Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
Nanomerics Ltd - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Nanomerics Ltd - Drug Profiles 12
amphotericin B nanoparticle 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
cyclosporine 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
NM-0127 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Antibodies for Neurological Diseases 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Drugs for Undisclosed Indication 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
NM-0132 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
NM-0134 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
NM-0141 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
NM-0151 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
NM-0161 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Nanomerics Ltd - Pipeline Analysis 22
Nanomerics Ltd - Pipeline Products by Target 22
Nanomerics Ltd - Pipeline Products by Route of Administration 23
Nanomerics Ltd - Pipeline Products by Molecule Type 24
Nanomerics Ltd - Pipeline Products by Mechanism of Action 25
Nanomerics Ltd - Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 27
Disclaimer 28

List of Tables
Nanomerics Ltd, Key Information 5
Nanomerics Ltd, Key Facts 5
Nanomerics Ltd - Pipeline by Indication, 2015 7
Nanomerics Ltd - Pipeline by Stage of Development, 2015 8
Nanomerics Ltd - Monotherapy Products in Pipeline, 2015 9
Nanomerics Ltd - Phase I, 2015 10
Nanomerics Ltd - Preclinical, 2015 11
Nanomerics Ltd - Pipeline by Target, 2015 22
Nanomerics Ltd - Pipeline by Route of Administration, 2015 23
Nanomerics Ltd - Pipeline by Molecule Type, 2015 24
Nanomerics Ltd - Pipeline Products by Mechanism of Action, 2015 25

List of Figures
Nanomerics Ltd - Pipeline by Top 10 Indication, 2015 7
Nanomerics Ltd - Pipeline by Stage of Development, 2015 8
Nanomerics Ltd - Monotherapy Products in Pipeline, 2015 9
Nanomerics Ltd - Pipeline by Top 10 Target, 2015 22
Nanomerics Ltd - Pipeline by Top 10 Molecule Type, 2015 24
Nanomerics Ltd - Pipeline Products by Top 10 Mechanism of Action, 2015 25

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing